Clinical trials: Bone Mass
Pulmonary Disease, Chronic Obstructive
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones.
- Trial name
- NCT00355342
- Testing
- Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
- Where
- 37 sites in United States
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Breast Cancer
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss
This study examines the safety and efficacy of zoledronic acid 4 mg., given every 3 months over 24 months (infusion at month 0, 3, 6, 9, 12, 15, 18 and 21) in improving bone mineral density in premenopausal women with hormone…
- Trial name
- NCT00375505
- Testing
- Zoledronic acid
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
This study will compare the effects of Zoledronic acid and Raloxifene in reducing bone turnover markers in postmenopausal women with low bone mineral density over 6 months.
- Trial name
- NCT00431444
- Testing
- Raloxifene, Zoledronic acid
- Where
- 17 sites in United States
- Volunteers
- 110 people
- Sponsor
- Novartis
Postmenopausal, Osteopenia
Effects of Denosumab on the Pharmacokinetics of Etanercept
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis…
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Trial name
- NCT01294397
- Testing
- Etanercept, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Osteoporosis
Effects of Proteins Fraction Derived From Milk on Osteoporosis Prevention
Osteoporosis is defined as a systemic skeletal disease characterised by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture.
- Trial name
- NCT01478724
- Testing
- Milk proteins fraction
- Where
- France
- Volunteers
- 291 people, healthy volunteers welcome
- Sponsor
- Soredab
Endometriosis
A Study to Assess the Effectiveness and Safety of Different Doses of ASP1707 Compared to Placebo for Endometriosis Associated Pelvic Pain
The main objective for this study is to assess the efficacy and dose-response relationship of ASP1707 in reduction of endometriosis associated pelvic pain.
- Trial name
- NCT01767090
- Testing
- ASP1707, Leuprorelin acetate
- Where
- 85 sites in Belgium, Bulgaria and 7 more
- Volunteers
- 912 people
- Sponsor
- Astellas Pharma Europe B.V.
Bone Loss
The Prevention Of Postmenopausal Osteoporosis With Lasofoxifene And Cytokine Evaluation
The objective of the study is to demonstrate the effects that lasofoxifene has on serum markers of bone metabolism.
- Trial name
- LACE (NCT00674453)
- Testing
- Lasofoxifene
- Where
- United Kingdom
- Volunteers
- 51 people
- Sponsor
- Ligand Pharmaceuticals
Osteopenia, Osteoporosis
Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density
This study is designed to provide information on the safety, tolerability, pharmacokinetics (PK) and bone biomarker response following multiple BPS804 administration in multiple dosing regimens.
- Trial name
- NCT01406548
- Testing
- BPS804 20mg/Kg
- Where
- 5 sites in United States
- Volunteers
- 44 people
- Sponsor
- Ultragenyx Pharmaceutical Inc
Post-Menopausal Osteoporosis
Intra-venous Zoledronic Acid Once Yearly
The study will assess the real life effectiveness of zoledronic acid in the management of patients with osteoporosis over 4 years of treatment.
- Trial name
- IVORY (NCT00984893)
- Testing
- zoledronic acid, Any oral bisphosphonates marketed in Canada
- Where
- 3 sites in Canada
- Volunteers
- 1,551 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis
A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women With Low Bone Mass
This is a double-blinded randomized study to determine the effects of treatment on biochemical markers of bone formation and bone resorption, and bone mineral density (BMD) for 6 months of treatment with EBP05 or placebo.
- Trial name
- NCT04003467
- Testing
- EBP05
- Where
- 4 sites in Israel
- Volunteers
- 161 people
- Sponsor
- Entera Bio Ltd.
Postmenopausal Osteoporosis
A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.
This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women.
- Trial name
- NCT00545051
- Testing
- ibandronate
- Where
- 15 sites in Finland
- Volunteers
- 140 people
- Sponsor
- Hoffmann-La Roche
Osteoporotic Fracture
Phase I Clinical Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of LYN101
This is a Phase 1, two-part, first-in-human, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of LYN101 in healthy subjects (part A)…
- Trial name
- NCT07178327
- Testing
- LYN101
- Where
- 2 sites in China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Shanghai TTM-Bio Technology Co., Ltd
Osteoporosis
RECONFIRM - Study of AGN1 LOEP in Patients with Osteoporosis
The research will be conducted as a prospective, post-market, multi-center study within Europe. The maximum number of subjects to be treated is 150 across up to 20 sites. This will be a non-randomized and open-label study.
- Trial name
- NCT05202678
- Testing
- AGN1 LOEP
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- AgNovos Healthcare, LLC
Osteoporosis, Bone Loss, Age-Related
ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients
This is a multi-center double-blind parallel-group study in involutional osteoporosis patients to compare the efficacy and safety of monthly oral intermittent formulation ONO-5920/YM529 with its daily formulation.
- Trial name
- NCT00794443
- Testing
- YM529 / ONO-5920
- Where
- 5 sites in Japan
- Volunteers
- 692 people
- Sponsor
- Astellas Pharma Inc
Endometriosis
Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
This study is designed to evaluate the safety and beneficial effects of elagolix (NBI-56418) compared to placebo and leuprorelin (an approved endometriosis therapy) over a three month period followed by an additional three months…
- Trial name
- NCT00797225
- Testing
- Leuprorelin Acetate Depot, Elagolix
- Volunteers
- 174 people
- Sponsor
- AbbVie
Postmenopausal Osteoporosis
A Trial Evaluating the Effects of Zoledronic Acid 5 mg Infusion on Bone Mineral Density (BMD) in Postmenopausal Osteoporosis (PMO) Patients Between the Ages of 50 and 65 Years
This study will evaluate the effects of zoledronic acid 5 mg infusion on BMD and biochemical markers of bone in post-menopausal osteoporotic patients aged between 50-65.
- Trial name
- NCT00909961
- Testing
- Zoledronic acid
- Where
- 6 sites in Turkey (Türkiye)
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Muscle Wasting (Atrophy) After Hip Fracture Surgery
Study of Efficacy and Safety of Bimagrumab in Patients After Hip Fracture Surgery
The purpose of this study was to assess if bimagrumab is safe and effective in patients with muscle wasting (atrophy) after hip fracture surgery.
- Trial name
- NCT02152761
- Testing
- bimagrumab
- Where
- 53 sites in United States, Argentina and 17 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis, Postmenopausal
A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab
The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.
- Trial name
- NCT01495000
- Testing
- denosumab
- Where
- 11 sites in India
- Volunteers
- 250 people
- Sponsor
- GlaxoSmithKline
Osteoporosis, Osteopenia
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects…
- Trial name
- NCT00330460
- Testing
- Alendronate, Denosumab
- Volunteers
- 1,189 people
- Sponsor
- Amgen
Uterine Fibroid, Endometriosis
Bone Mineral Density in Women With Uterine Fibroids or Endometriosis
The purpose of this study is to characterize the longitudinal bone mineral density (BMD) in premenopausal women with uterine fibroids or endometriosis.
- Trial name
- NCT03744507
- Where
- 63 sites in United States, Australia and 5 more
- Volunteers
- 660 people
- Sponsor
- Myovant Sciences GmbH